Previous Article | Next Article 
Molecular and Cellular Biology, January 2001, p. 614-623, Vol. 21, No. 2
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.2.614-623.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Prodos Is a Conserved Transcriptional Regulator
That Interacts with dTAFII16 in Drosophila
melanogaster
Angel
Hernández-Hernández and
Alberto
Ferrús*
Instituto Cajal, C.S.I.C., Madrid 28002, Spain
Received 6 July 2000/Returned for modification 29 August
2000/Accepted 16 October 2000
 |
ABSTRACT |
The transcription factor TFIID is a multiprotein complex that
includes the TATA box binding protein (TBP) and a number of associated
factors, TAFII. Prodos (PDS) is a conserved protein that
exhibits a histone fold domain (HFD). In yeast two-hybrid tests using
PDS as bait, we cloned the Drosophila TAFII,
dTAFII16, as a specific PDS target. dTAFII16 is
closely related to human TAFII30 and to another recently
discovered Drosophila TAF, dTAFII24. PDS and
dTAFII24 do not interact, however, thus establishing a functional difference between these dTAFs. The PDS-dTAFII16
interaction is mediated by the HFD motif in PDS and the N terminus in
dTAFII16, as indicated by yeast two-hybrid assays with
protein fragments. Luciferase-reported transcription tests in
transfected cells show that PDS or an HFD-containing fragment activates
transcription only with the help of dTAFII16 and TBP.
Consistent with this, the eye phenotype of flies expressing a
sev-Ras1 construct is modulated by PDS and
dTAFII16 in a gene dosage-dependent manner. Finally, we
show that PDS function is required for cell viability in somatic
mosaics. These findings indicate that PDS is a novel transcriptional
coactivator that associates with a member of the general transcription
factor TFIID.
 |
INTRODUCTION |
One of the first events in
transcription of protein-encoding genes is the assembly of a
preinitiation complex that contains RNA polymerase II and general
transcription factors such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH,
and TFIIJ (24, 52, 56). Assembly is thought to be a
sequential process initiated by the nucleation of transcription factors
to core promoters or, alternatively, the attachment of preformed
complexes, holoenzymes, to target DNA sequences (36).
TFIID is a multiprotein complex formed by the TATA-binding protein
(TBP) and several TBP-associated factors, TAFIIs (23, 31, 38, 66, 70). TAFIIs are named according to their
apparent or estimated molecular weight (e.g., TAFII30,
TAFII105). They are present not only in TFIID but also in
other complexes that play additional roles in chromatin remodeling and
gene transcription, such as SAGA, PCAF, and TFTC (22, 43, 51, 63,
75). Their presence in multiple protein complexes reflects a
variety of functional roles and protein interactions. Some
TAFIIs are thought to mediate promoter recognition and
selectivity (8, 61, 69). Human TAFII250
exhibits histone acetylase and protein kinase activities that modulate
chromatin structure as well as the activity of general transcription
factors (11, 46, 49). Other TAFIIs are thought to act as cofactors, since they associate with specific transcription activators. For example, hTAFII130 and its
Drosophila homologue, dTAFII110, interact with
Sp1 (29, 57, 65) and with the cyclic AMP response
element-binding protein (13, 14, 58). In addition, hTAFII105 interacts with NF-
B (77). In
vitro experiments using reconstituted TFIID complexes demonstrated a
synergistic interaction between two activators, Bicoid and Hunchback,
and specific TAFIIs, TAFII110 and
TAFII60 (59). In vivo studies in
Drosophila support the hypothesis that TAFIIs
may serve as targets for enhancer-binding proteins (54,
78). On the other hand, TAFIIs may also serve to
mediate signaling pathways; this is the case for hTAFII55, hTAFII30 and hTAFII28, which bind to nuclear
receptors for thyroid hormone, estrogen, and retinoic acid,
respectively (37, 44). Likewise, hTAFII31
interacts with p53 (40) whereas dTAFII40 interacts with VP16 (21, 35) and p53 (67).
TAFIIs thus contribute to gene regulation, acting as
cofactors in a wide repertoire of interactions with transcription factors.
Nonetheless, under certain conditions, TAFIIs may not be
obligatory components of activated transcription. Yeast and HeLa cells
depleted of major TAFIIs can form preinitiation complexes in a single-round transcription assay (47, 50, 71).
Although it is possible that TAFIIs are not always required
for transcription initiation, it is clear that they are essential for
the functional expression of specific genes. In yeast and mammals,
TAFII mutations cause cell cycle arrest at phases specific
to each TAFII (1, 42, 45, 72, 73). In
Drosophila, mutations in TAFII110, TAFII250, and TAFII60 yield lethal phenotypes
(FlyBase, on http://flybase.bio.indiana.edu). For any particular type
of TAFII, sequences are significantly conserved among
yeast, flies, and humans (23, 66). Thirteen are known so
far, and this number is not likely to increase much further since the
identification has been carried out mostly through direct biochemical
purification of whole complexes. Although several of them are usually
present in any given complex, it seems that the exquisite control of
gene transcription would require a larger repertoire of regulators. It
is in this context that the PDS-TAFII16 interaction
described here becomes relevant.
prodos (pds) is a recently discovered vital gene
from the 16F cluster in the X chromosome of Drosophila
(55). The corresponding protein, Prodos (PDS) (submitted
to the EMBL database under accession number Y15513), is rich in proline
residues and contains a histone fold domain (HFD). This motif is
thought to mediate DNA-protein and protein-protein interactions
(2) and is found in the four core histones
(4) as well as in several TAFIIs (6, 18, 30, 76). The pds gene is expressed throughout
development in all tissues analyzed, and the protein localizes to
nuclear extracts (our unpublished data). The conserved sequence and the general expression of the gene suggested a basic role in cell biology;
we thus set out to identify proteins that might interact with PDS. The
yeast two-hybrid test led to the cloning of a new Drosophila
TAFII, dTAFII16, with significant homology to
human TAFII30. We report the characterization of this
member of the TAFII family in Drosophila and its
physical interaction with PDS in vivo and in vitro through the N
terminus and the HFDs, respectively. We also demonstrate that this
association activates gene transcription in transfected cells and that
both proteins modulate the expression of a gene construct in the organism.
 |
MATERIALS AND METHODS |
Fly strains and genetic procedures.
The mutation
pds2270 is an ethyl methanesulfonate
(EMS)-induced allele of pds, and
pds88 is a P element insertion located 17 bp
upstream of the ATG initiation site in the transcription unit (our
unpublished data). Deletions Df(1)88-6 and
Df(1)88-2 were generated by remobilization of the P insert
and characterized by genetic and molecular procedures. Df(1)88-6 deletes approximately 4 kb from the insertion site
toward the telomere and removes the adjacent vital gene,
HL-XIV, but not scully (55, 68).
Df(1)88-2 deletes from the insertion site toward the
centromere without affecting the adjacent gene, HL-VII. The
pds+ transgene was supplied by the genomic
fragment E6L, which contains the complete open reading frame (ORF) and
is able to rescue the pds phenotype (55). Two
independent viable insertions of genomic transformants,
T(2)E6L and T(3)E6L, in the autosomes were
tested, yielding the same results. The Df(2)N6 and
Df(2)N19 chromosomes were from the Bloomington Stock Center
(Indiana University, Bloomington, Ind.). These deficiencies delete the
dTAFII16 gene, as we confirmed by PCR. The
sev-Ras1V12 construct used was from the CyO-CR2
chromosome, provided by the Umea stock center (Umea University, Umea,
Sweden). Enhancers in sev-Ras1V12 consist of
three copies of the genomic fragment from 7134 to 7833, whereas those
in sE-raftorY9 and
sev-hsp-ro correspond to two copies of the fragment from 7319 to 8536 (3, 7). The sev promoter is the
fragment from the sevenless gene from
966 to 88, whereas
the hsp promoter is the fragment from the hsp70
gene from
250 to 90. The sE-raftorY9
and sev-hsp-ro constructs were provided by E. Hafen
(Zürich University, Zürich, Switzerland). Scanning electron
micrographs were obtained using Philips XL-30 equipment. Mosaics were
generated by X-ray-induced recombination in two genotypes, y w
pds2270/f36a and y
w pds2270/M(1)n. In the first case, most crossovers
are expected to occur between the centromere and the pds
locus because of the large amount of intervening DNA. These
crossovers generate twin spots that should grow to the same size. In
the second case, the mutant clones have a growth advantage over their
adjacent nonmutant cells, the M+ condition
(15).
Plasmid constructs.
All plasmids used in the yeast
two-hybrid assays were generated by PCR using suitable oligonucleotides
and compatible restriction sites. The resulting products were cloned
into pACT2 and pAS2-1, which encode the Ga14 activation domain and
DNA-binding domain, respectively (Clontech). To generate expression
vectors for the fusion protein between
glutathione-S-transferase (GST) and PDS, GST-PDS,
full-length pds cDNA was SmaI-EcoRI
digested from pAS2-1-PDS and cloned into pGEX. His-tagged full-length
dTAFII16 cDNA was likewise amplified by PCR and cloned into
pRSET. TBP and PDS were fused to a triple HA epitope tag, and
dTAFII16 was fused to six myc epitope tags at the start
codon by PCR and cloned into RactHAdh (64). The fusion
product of PDS and the Ga14 DNA-binding domain was amplified from
pAS2-1-PDS and subcloned into RActHAdh. Constructs (G4)5-HSV-TK-Luc and pPac-
gal were a gift of R. Tjian
(University of California, Berkeley, Calif.). We generated the
construct sev-Luc by replacing the (G4)5-HSV-TK
region of the previous vector with the same regulatory (enhancer and
promoter) sequences of the sev-Ras1V12 construct
(see above). The sev promoter was obtained from vector pSP/HSS and the enhancers were from pSE8/DM30, supplied by D. A. Wassarman (National Institutes of Health, Bethesda, Md.). All plasmids
were verified by DNA sequencing. Further details of construct procedures are available on request.
Yeast two-hybrid assay.
The full-length PDS cDNA was used as
bait. The cDNA was cloned in plasmid pAS2-1 and introduced into the
yeast strain Y190. Colonies expressing the Ga14 DNA-binding domain
fused to PDS were identified by immunoblotting with anti-PDS antibody.
The second component of the assay, the Ga14 activation domain, was
supplied as an embryo cDNA library in pGAD10 (Clontech). The subsequent transformation followed standard procedures (27). A total
of 1.4 × 107 library transformants were screened in
this manner.
Validation of yeast two-hybrid transformants.
Of 312 transformants able to grow in synthetic complete (SC) medium lacking
histidine, only 76 contained plasmids that activated lacZ
transcription. To further eliminate false positives, we provoked the
loss of "bait" plasmids by streaking the transformants on SC medium
containing 2.5 mg of cycloheximide per ml (27). Plasmid loss was verified by replica plating on SC medium lacking tryptophan and leucine. Transformants were mated subsequently to Y187 yeast strains containing pAS2-1-PDS, pAS2-1 alone, or pLAM5'-1 (which expresses a fusion of Ga14 DNA-binding domain and human lamin C).
Eleven false positives were discarded since they could activate lacZ transcription in the absence of PDS. Analysis showed
that they all encoded typical false positives (28). The
remaining clones contained plasmids that activated lacZ
transcription only in the presence of the Ga14 DNA-binding domain
fusion and PDS but not in the presence of pAS2-1 alone or pLAM5'. In
addition, the interaction persisted after plasmid swapping between PDS
and the isolated positive clones. Since they fulfilled all possible controls of the yeast two-hybrid assay, we therefore considered the
resulting 69 clones to be true positives.
Northern blot analysis and DNA cloning.
Poly(A)+
mRNA was isolated using a QuickPrep Micro mRNA purification kit
(Pharmacia Biotech). mRNA (5 µg) from each sample was loaded on 1.5%
agarose-formaldehyde gels and transferred to nylon membranes
(Bio-Rad). The probe was [
-32P]dATP radiolabeled by
the random-priming method (12). Transcript size was
estimated using RNA markers (Gibco-BRL). The partial cDNA found in the
yeast two-hybrid assay was used as a probe to screen an adult head
gt11 cDNA library (from E. Meyerowitz, Caltech) at high stringency.
Immunological procedures.
To immunize rabbits, the
His-dTAFII16 fusion protein was affinity purified using
Ni-nitrilotriacetic acid agarose column (Qiagen). The
anti-dTAFII16 monospecific antibody was affinity purified from crude sera using a GST-dTAFII16 column (Pharmacia
Biotech) (26) and used for immunoblotting and
immunostaining. Whole embryos and third-instar larvae were dissected
and fixed for 30 min in freshly prepared 4% paraformaldehyde in
phosphate-buffered saline (PBS). Specimens were incubated in crude
rabbit serum (1:1,000) or monospecific anti-dTAFII16
(1:200) overnight at 4°C in PBT (0.1% Triton X-100 in PBS),
thoroughly washed in PBT, and incubated for 1 h at room
temperature in secondary anti-rabbit immunoglobulin G antibody
conjugated to Cy3 (Amersham). Preparations were mounted in PBS-glycerol
(1:1) and viewed under a confocal microscope (Leica). The anti-myc
antibody (1-9E10.2) was a gift of S. Pons (Instituto Cajal, Madrid,
Spain), and the anti-HA antibodies (rabbit Y-11 and mouse F-7) were
from Santa Cruz Biotechnology.
GST pull-down experiments.
The procedure used for the GST
pull-down assay was essentially as described elsewhere
(53). Briefly, GST or GST-PDS proteins (5 µg)
immobilized on agarose resin (Pharmacia Biotech) were washed extensively with LBST-100 buffer (25 mM HEPES-KOH [pH 7.9], 100 mM
NaCl, 6% glycerol, 5 mM MgCl, 1 mM dithiothreitol, 0.05% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 mM EDTA).
His-dTAFII16 fusion protein (5 µg) was added to the
resins, and the interaction assay was carried out in a final volume of
300 µl (for 2 h at 4°C) with gentle shaking. The beads were
washed four times with increasing NaCl concentrations (LBST-100,
LBST-300, and LBST-500), and the bound proteins were analyzed by
immunoblotting using anti-dTAFII16 antibody.
Cell transfection and immunoprecipitation.
Schneider line 2 cells were transfected by the calcium phosphate method (9)
at a density of 6 × 106 cells per plate, using 5 µg
of plasmid DNA for transfection. After 48 h, the cells were
harvested by three freeze-thaw cycles in buffer A (10 mM HEPES-KOH [pH
7.6], 100 mM NaCl, 10% glycerol, 8 mM MgCl, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 0.2 mM EDTA) if they were used for
immunoprecipitation or in reporter assay buffer (Promega) if they were
used for determination of luciferase activity. A 20-µl volume of
cleared lysate was used for each luciferase (Promega) and
-galactosidase assay, and luciferase activity was normalized to that
of
-galactosidase. For immunoprecipitation, 100-µl volumes of cell
extracts were incubated (for 2 h at room temperature) with 2 µg
of the indicated antibody in buffer A to a final volume of 400 µl.
Following this, 20 µl of protein A/G agarose (Santa Cruz
Biotechnology) was added, and the incubation was continued for 1 h
at 4°C. The resin was extensively washed with buffer A, and the bound
material was analyzed by immunoblotting. Analysis of the potential
interaction is complicated by the fact that the protein constructs,
HA-PDS and myc-dTAFII16, have molecular weights very
similar to those of the heavy and light immunoglobulin G chains
respectively. To avoid this problem, we immunoprecipitated them with a
rabbit anti-HA polyclonal (Y-11) and analyzed the result with mouse
monoclonal anti-HA (F-7) and anti-myc (1-9E10.2) antibodies.
Nucleotide sequences accession numbers.
dTAFII16
and dTAFII24 sequences have been submitted to the EMBL
database under accession numbers AJ237968 and AJ276419, respectively.
 |
RESULTS |
PDS interacts with a new Drosophila
TAFII.
To identify proteins that might
interact with PDS, we carried out a yeast two-hybrid screen using a
previously isolated (our unpublished data) full-length pds
cDNA as bait (16). Of 1.4 × 107 clones
screened, 69 true positives were isolated from the initial 76 transformants (see Materials and Methods). On sequencing, all 69 clones
were found to contain an identical insert of 485 bp. This large number
of clones probably results from the high efficiency of the
transformation process. Using this insert as a probe, we screened an
adult head cDNA library and isolated a transcript 17 bp longer, which
includes a putative translation start site. A polyadenylation consensus
signal is located at position 482 (74), but no splice
signals are found (48), and comparison with the
corresponding genomic sequence does not reveal alternative splicing. Furthermore, expressed sequence tag (EST) database
searches revealed one EST (accession number AI388776) with a sequence identical to that of our cDNA, which was reported to the EMBL database under accession number AJ237968. A more recent report indicates the presence of a longer (770-bp) cDNA (accession
number AJ243837) (19). The ORF in both sequences,
however, are coincident, and the discrepancy between the two mRNA sizes
[0.7 and 0.95 kb respectively, including the poly(A) tracts] pertains
to the 5' untranslated region only. The conceptual translation of the
single ORF produces a 146-amino-acid protein with significant identity to human TAFII30 (Fig. 1).
The theoretical molecular mass of the Drosophila protein is
16 kg mol
1. Based on this value and the sequence
identity to hTAFII30, we named the gene
dTAFII16. Northern blot analyses indicate that the gene is expressed as a single mRNA band detected throughout all
developmental stages (Fig. 2). The size
of our cDNA matches that of the corresponding mRNA relatively well,
after allowing for poly(A) tracts. The broad band indicates a size of
530 to 700 bp and suggests different levels of polyadenylation. To
resolve the cellular localization of the protein, we stained larvae
with a monospecific anti-dTAFII16 antibody using the
preimmune serum as a negative control. The specific signal was detected
exclusively in the nuclei of all cell types at all developmental stages
including the blastoderm prior to cellularization (Fig. 2). At variance with a recent report (19), we failed to detect any
cytoplasmic signal. To address this discrepancy, we transfected cells
with an expression vector containing myc-tagged dTAFII16
and stained them with an anti-myc antibody (see below). This procedure
confirmed the nuclear localization (data not shown). Within the
nucleus, dTAFII16 is localized in multiple hot spots,
leaving a single (occasionally double) major signal-deprived site that
seems to correspond to the nucleolus (Fig. 2F).

View larger version (109K):
[in this window]
[in a new window]
|
FIG. 1.
Protein sequence alignment among
dTAFII16, dTAFII24, and hTAFII30.
Identical residues are shaded. Note the high sequence conservation
toward the C terminus. Accession numbers for dTAFII16 and
dTAFII24 are AJ237968 and AJ276419, respectively.
|
|

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 2.
dTAFII16 expression. (A) Developmental
Northern blot hybridized with the 502-nucleotide adult head cDNA probe.
(B to F) Confocal images of immunostaining with a crude
anti-dTAFII16 rabbit serum (B to E) or a monospecific
anti-dTAFII16 antibody (F) visualized by fluorochrome Cy3.
(B) Preblastoderm stage during cellularization. (C) Blastoderm stage.
(D) Embryo stage 15 showing the central nervous system, muscles, and
epidermis. (E) Third-instar imaginal wing disk. Note the nuclear
localization of the signal in all tissues and developmental stages. (F)
Detail of two Malpighian tubule cells. Note the spotty signal within
the nucleus, except for the nucleoli, and its absence from the
cytoplasm. Bar, 12 µm (B), 130 µm (C), 190 µm (D), 30 µm (E),
and 2 µm (F).
|
|
The PDS-dTAFII16 interaction is reproduced in vitro and
in vivo.
The isolation of a large number of identical interactors
in the yeast two hybrid assay suggested that their binding is relevant. To further analyze the association of PDS and
dTAFII16, we carried out GST pull-down and
coimmunoprecipitation (co-IP) assays. For the in vitro GST pull-down
experiment, dTAFII16 was tagged with histidine
(His-dTAFII16) and PDS was fused to GST.
His-dTAFII16 was eluted through two types of agarose
columns, with bound GST-PDS or GST alone. The experiment was performed
three times, yielding reproducible results. His-dTAFII16
binds to GST-PDS but fails to bind to GST alone (Fig.
3A), indicating that the interaction is
specific, at least in this in vitro assay. In vivo evidence for
this association was obtained in a co-IP assay (Fig. 3B). Two types of
plasmids expressing myc-tagged dTAFII16
(myc-dTAFII16) and hemagglutinin-tagged PDS (HA-PDS)
were used to transiently transfect Schneider 2 cells. The expression of
both proteins was verified in blots stained with antibodies against myc
and HA tags. Mouse monoclonal anti-myc and rabbit polyclonal anti-HA
antibodies were used for IP. Anti-myc precipitates were probed with a
rabbit polyclonal anti-PDS (Fig. 3B, lane 1), stripped, and reprobed with anti-myc antibody (lane 2). Conversely, precipitates elicited by
rabbit polyclonal anti-HA antibody were probed with a mouse monoclonal anti-HA and the anti-myc antibodies (lane 3). The data show that anti-HA antibody precipitates myc-dTAFII16
when coexpressed with HA-PDS and anti-myc antibody does so with HA-PDS
when coexpressed with myc-dTAFII16. Irrespective of the
antibody used to elicit IP, therefore, there is co-IP of the other
protein partner. As negative controls (data not shown), in cell
extracts transfected with single constructs, HA-PDS precipitates
with anti-HA but not with anti-myc whereas
myc-dTAFII16 precipitates only with anti-myc. These
results demonstrate that the PDS-TAFII16 association is specific and takes place in living cells, most probably in the nucleus,
where both localize.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Physical association of PDS with
dTAFII16. Abbreviations: (A) GST pull-down experiment
between a GST-PDS fusion protein and a histidine-tagged
dTAFII16. (B) Coimmunoprecipitation of HA-tagged PDS with
myc-tagged dTAFII16. The antibodies used for the
immunoprecipitation (IP) are indicated above each lane. The blot in
lane 1 was probed with anti-PDS antibody, stripped, and reprobed with
anti-myc antibody ( -myc) (lane 2). The anti-PDS antibody thus
reveals the HA-tagged as well as the constitutive PDS products. In lane
3, the precipitate was induced with rabbit anti-HA antibody ( -HA)
and then probed with mouse anti-HA antibody (see Materials and Methods)
in addition to the anti-myc antibody.
|
|
The interaction is mediated by the PDS HFD and the
dTAFII16 amino terminus.
PDS contains a putative HFD
between amino acids 12 and 82. In addition, abundant proline residues
are found C-terminal to this domain, albeit not clustered in a
recognizable motif. The yeast two-hybrid system using eight different
PDS fragments served to dissect the PDS domain responsible for the
interaction with dTAFII16 (Fig.
4). The same control procedures as in the
yeast two-hybrid screen were used. All N-terminal fragments that
included the first 90 amino acids of PDS were able to bind
dTAFII16, whereas those comprising only the C-terminal
regions did not. In addition, a small fragment including the HFD motif
(PDS1-91) sustained the interaction whereas fragments that
split HFD (PDS1-47 and PDS40-124) did not.
HFD thus appears necessary and sufficient to mediate the binding
between PDS and dTAFII16. Although dTAFII16 is
a small protein without recognizable structural motifs, we attempted to
identify a putative critical region for the interaction with PDS. The
three fragments used (Fig. 4B) allowed identification of the N terminus
as a requirement for this association. Attempts to further subdivide
this region failed to sustain the interaction.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 4.
Dissection of the interaction of PDS and
dTAFII16 in yeast. (A) Interaction of PDS fragments with
dTAFII16. The HFD motif in PDS extends from amino acids 12 to 82. (B) Interaction of dTAFII16 fragments with PDS.
|
|
PDS activates transcription in cells.
To test the biological
significance of the interaction described above, we tested its role in
gene transcription by using transfected Schneider 2 cells. As a
reporter, we monitored the enzymatic activity of luciferase. The
luciferase cDNA is under the control of the herpes simplex virus
thymidine kinase promoter fused to an enhancer element containing five
upstream activation sequence sites (Gal4 targets). lacZ
under the control of the actin promoter, which contains neither
enhancers nor Gal4 sites, served as an internal reference. The reporter
and the internal control were transfected in the absence or presence of
plasmids driving the expression of Gal4-PDS, myc-dTAFII16,
or HA-TBP. Transfection with Gal4-PDS or myc-dTAFII16 had
no effect on luciferase activity with respect to basal levels.
Transfection with HA-TBP, alone or in addition to
myc-dTAFII16 or Gal4-PDS, led to relatively weak
activation. Following cotransfection with the three proteins (Gal4-PDS, myc-dTAFII16, and HA-TBP), however, a
strong increase in luciferase activity (18-fold with respect to the
basal level) was detected (Fig. 5A). The
experiment was reproduced four times, yielding consistent results. The
activation levels observed with the three proteins are equivalent to
those reported in a similar experiment using the transcriptional
activator SplA (see Fig. 3C in reference 25). Transfection
with Gal4-PDS, alone or in addition to mycTAFII16 or
HA-TBP, failed to elicit significant levels of activation. This
observation would argue against a role for PDS as a transcriptional
activator, since the endogenous TFIID components, including
TAFII16 which is expressed in Schneider 2 cells (data not
shown), may have contributed to the putative role of PDS. It should be
noticed, however, that the transcriptional activity of the luciferase
reporter in this type of cell depends on the high expression levels of
the transfected plasmids. It is quite likely that if any one of the
required components is present at low concentration, it will become a
limiting factor. In fact, this is the key feature on which this test is
based. Comparing the activation levels elicited by each protein
combination, we can conclude that PDS is able to activate
transcription when fused to Gal4 using dTAFII16 as a
cofactor. This experiment provides additional evidence on two important
issues, (i) that the PDS-TAFII16 interaction occurs in vivo
and (ii) that dTAFII16 is a bona fide TAFII
because it requires TBP to promote gene transcription.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 5.
PDS and dTAFII16 mediate transcription
activation. Schneider 2 cells were cotransfected with PDS,
TAFII16, and TBP in various combinations of tagged products
(see the text). A 5-µg sample of each plasmid DNA was used. Histogram
values indicate the recorded luciferase activity normalized with
respect to the internal control of -galactosidase ( -gal) (see
Materials and Methods). Basal activity refers to the data obtained
after transfection with luciferase- and lacZ-containing
plasmids. (A) Assays with full-length PDS fused to Gal4BD. (B) Assays
with a PDS fragment that includes the HFD motif. HSV Tk, herpes simplex
virus thymidine kinase.
|
|
In line with the data from the yeast two-hybrid test, we assayed
whether a PDS fragment containing the HFD motif will be able to
activate transcription of the luciferase reporter; Fig. 5B shows that
this is the case. The same small PDS fragment, PDS1-91, used in the yeast two-hybrid tests yielded significant activation only
if co-transfected with TAFII16 and TBP. This result
demonstrates that the activation effect observed with the whole PDS
protein can be reproduced (70% activation with respect to the whole
PDS protein) by a fragment including the HFD motif, further supporting the role of this structural motif in the interaction with
dTAFII16. The data obtained so far indicate that the
function of PDS in Drosophila might be to activate gene
transcription by recruiting dTFIID components.
PDS and dTAFII16 modulate phenotype expression in
Drosophila.
The expression of a constitutively active
Ras1 allele under the control of eye-specific
sevenless regulatory sequences
(sev-Ras1V12) resulted in the transformation of
cone cells into R7 photoreceptors, which roughen the eye (compare Fig.
6A and C) (17). This effect has been instrumental in isolating components of the Ras1
signaling pathway (33). Mutations that modify this
phenotype are candidate genes for components of the Ras1
signaling cascade or transcription factors that control the expression
of the sev-Ras1V12 construct or its downstream
genes. In this way, several TAFIIs have been identified as
mutant suppressors of the rough eye phenotype (60). We
used the same approach to test the potential effects of PDS and
dTAFII16. The data show that the
sev-Ras1V12 phenotype is modulated by PDS in a
gene dosage-dependent manner. Heterozygotes for mutant alleles
(pds2270 and pds88) or
deletions [Df(1)88-6 and Df(1)88-2] of
the gene partially suppressed the eye roughening (Fig. 6B),
whereas increased expression of PDS (Fig. 6D and E) using one or
two copies of a pds+ transgene (see Materials
and Methods) progressively aggravated it. The suppression effect was
also observed in heterozygotes of dTAFII16 deletions
[Df(2)N6 and Df(2)N19] (Fig. 6F). In this case,
however, increased dosage could be assayed since
dTAFII16+ transgenes are not yet
available. The combined reduction of gene dosage for PDS and
dTAFII16 did not show further suppression of the
sev-Ras1V12-induced eye phenotype (data not
shown). Taken together, these observations indicate that both proteins
act through the same mechanism or pathway.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 6.
PDS and dTAFII16 modulate the
phenotypic expression of a sev-Ras1V12
construct. Representative scanning electron micrographs of eyes of
adult females expressing one copy of the
sev-Ras1V12 construct with variable number of
pds+ gene copies. (A) Wild type; (B)
pds2270/+; CyO-CR2,
sev-Ras1V12/+; (C) CyO-CR2,
sev-Ras1V12/+; (D) CyO-CR2,
sev-Ras1V12/+;T(3)E6L/+; (E) CyO-CR2,
sev-Ras1V12/+;T(3)E6L/ T(3)E6L; (F)
CyO-CR2, sev-Ras1V12/Df(2) N6.
Numbers 1 to 4 above each panel indicate the number of functional
copies of pds+ in the corresponding genotypes.
Note the pds gene dosage dependence of the eye-roughening
phenotype. Also note in panel F the partial suppression elicited by the
heterozygous deletion for dTAFII16. Consistent
results were obtained with other pds
[Df(1)88-6 and Df(1)88-2] or
dTAFII16 [Df(2)N19]
chromosomes (data not shown). Anterior is to the left, dorsal is up.
Bar, 90 µm. The diagram shows the structures of the three
eye-roughening producing constructs assayed.
|
|
In an attempt to discriminate between PDS and dTAFII16
affecting sev-Ras1V12 transcription or the
subsequent signaling cascade, we assayed two other available
constructs, sE-RaftorY9 and
sev-hsp-ro. The three constructs differ in the
enhancer/promoter sequences or the gene driven (Fig. 6). The previous
gene dosage genotypes involving PDS or dTAFII16 show no
modification of the eye phenotype elicited by either construct (data
not shown). Since Ras1 and Raf activate the same
or very similar pathways, it is unlikely that the differential effect
observed with these two constructs could be attributed to a selective
effect of PDS and dTAFII16 on genes in the cascade.
Similarly, the lack of effect the sev-hsp-ro construct
points to the sev promoter as a likely target for
PDS-dTAFII16. Since the genomic segments containing the
sev enhancers are not identical between the first two
constructs, however, sev enhancers cannot be formally
excluded as a target for PDS-dTAFII16. To further explore
the role of PDS on transcription activation, and in particular whether
PDS could target the sevenless promoter or enhancer
sequences, we assayed a novel luciferase-expressing construct,
sev-luc, containing the same regulatory sequences as the
sev-Ras1V12 construct (see Materials and
Methods). No significant effect on luciferase expression was found in
cells transfected with PDS, dTAFII16, TBP, or their
combinations (data not shown). This result indicates that PDS is
unlikely to be a transcriptional activator per se or, alternatively,
that its native target is not included in the
sev-promoter/sev-enhancer sequences. Nonetheless,
since both the Gal4-driven luciferase transcription in cells and the sev-driven Ras1 phenotypes in flies indicate that
PDS plays a role in activation, it can be concluded that PDS is a
coactivator that recruits components of the TFIID and requires an
additional mechanism to bind DNA.
Exploring interactions with other TFIID
components.
hTAFII30 is reported to
interact with TBP, hTAFII250, hTAFII20,
and itself, forming homomultimeres (32). Using the yeast two-hybrid system, we tested whether dTAFII16 could
interact with dTBP, dTAFII30
(the Drosophila
homologue of hTAFII20), or itself. All these assays yielded
negative results (data not shown), suggesting that hTAFII30
and dTAFII16 do not sustain the same interactions within
TFIID. EST database searches revealed another Drosophila EST
(accession number AI457031), however, encoding a protein very
similar to dTAFII16 and hTAFII30. The gene maps
to the 23A6-7 chromosome band, adjacent and in opposite orientation to
dTAFII16. We sequenced this genomic region
and the EST in full to confirm the ORF. The revised sequence has been
submitted to the EMBL database (accession number AJ276419). It
indicates a second hTAFII30 homologue, with a theoretical
molecular mass of 18.5 kg mol
1. Both
Drosophila homologues of hTAFII30 have been
reported recently, and the name dTAFII24 was assigned to
the second element (19). Given the similarity between
dTAFII16 and dTAFII24, we used the yeast
two-hybrid assay to find whether PDS would interact with the new
homologue; the result was negative. In addition, since the N terminus
of dTAFII16 mediates the interaction with PDS (Fig. 4B) and
since both dTAFIIs deviate in their N-terminal sequences (Fig. 1), it is likely that this part of the protein sustains differential interactions of these TAFIIs. These results
demonstrate that dTAFII16 and dTAFII24 are
functionally distinct. Nevertheless, we further assayed whether
dTAFII16 and dTAFII24 could interact in
Drosophila, mimicking the reported homodimerization of
hTAFII30. The result from the yeast two-hybrid assay was,
however, negative (data not shown). The same experimental approach also
yielded a negative result to the question whether PDS could interact
directly with TBP. This last observation is coherent with the
requirement for the triple cotransfection (PDS, dTAFII16,
and TBP) in the transcription activation assays (Fig. 5).
pds function is required for cell survival.
The
cellular effects of PDS depletion can be evaluated in mosaics. To that
end, transheterozygous y w
pds2270/f36a larvae were
irradiated to obtain marked twin spots screened in the dorsal notum. In
addition, y w pds2270/M(1)n larvae were
similarly treated to generate w pds2270
M+ clones marked in the eye. No mutant clones were
detected in either system, and control cases appeared at the expected
ratios (Table 1). It should be noted that
mutant eye cells, which are M+, would have had a
growth advantage over the surrounding cells (15). These
data demonstrate that PDS is a cell vital function, at least for
integument cells.
 |
DISCUSSION |
The data show that Drosophila PDS and
TAFII16 interact specifically, leading to transcription
activation through the TFIID complex. The structural motifs in each
protein that mediate the interaction have been dissected, and the
results indicate that PDS should be considered a coactivator of gene
expression. Since PDS is a vital cell function and since both proteins
are expressed in all cell types, it can be deduced that the interaction
is functional in many genes. In addition, since both proteins appear to
have conserved homologues and requirements, their interaction is
expected to be functional in mammals as well.
Functional interaction of the HFD.
PDS fragments that contain
the HFD motif sustain the PDS-dTAFII16 association,
demonstrating that this is a functional domain. For the other partner,
dTAFII16, the N terminus is necessary and sufficient for
the interaction to take place. HFD is a motif conserved in all core
histones and several TAFIIs. It is formed by a long central
-helix flanked by two smaller ones. The central helix acts as a
dimerization interface in a head-to-tail fashion described as a
"handshake" structure (2, 76). To date, most
HFD-mediated interactions have been documented between proteins
containing the same motif. A precedent for interaction between HFD- and
non-HFD-containing proteins is, nonetheless, known for the trimeric
CBF/NF-Y transcription factor (41). The case of
PDS-dTAFII16 reported here would add another such example.
Current databases include over 1,000 HFD-containing proteins
(5), suggesting that the number and diversity of processes mediated by this motif will increase substantially.
The association has been reproduced both in vitro and in vivo, showing
that it is specific and functionally relevant for gene transcription.
Further, the luciferase transcription assay demonstrates that the
functional expression of this interaction also requires TBP. This
result argues in favor of TFIID as the likely transcription factor
through which PDS elicits transcription activation.
dTAFII16 has recently been shown to participate in TFIID
but not in other complexes (19). Moreover, the absence of
dTAFII16 from nucleoli is consistent with the fact that
ribosomal gene transcription does not involve TFIID.
Two conserved proteins, PDS and dTAFII16.
pds is a recently discovered Drosophila gene (our
unpublished data) (accession number Y15513). Databases also include the murine protein Taube nuss (accession number AAG01682), which is 35%
identical to PDS and has an HFD motif toward its N terminus (Fig.
7). In addition, we found that PDS is a
vital cell function in Drosophila and Taube is reported to
be essential for pluripotent cells in the mouse. Based on these
structural and functional features, it is likely that the two proteins
are homologues. Among human database sequences, a clot (Hs. 139179) of
eight ESTs (accession numbers AI151131, AI027324, AI027325, AI655948,
AI738942, AA983184, AA641254, and N71758) also shows close homology to
the Drosophila PDS.

View larger version (106K):
[in this window]
[in a new window]
|
FIG. 7.
Protein sequence alignment between PDS and the
recently reported murine protein Taube nuss. Identical residues are
shaded. Note the presence of a HFD domain (shaded) in both proteins.
Accession numbers for PDS and Taube are Y15513 and AAG01682,
respectively.
|
|
Although dTAFII16 and dTAFII24 are considered
sequence homologues of hTAFII30, detailed analysis of the
three protein sequences indicates that dTAFII16 is a closer
relative of hTAFII30 (45% identity) than of
dTAFII24 (38% identity). The two protein sequences diverge
in their N terminus, and this is the region that mediates the selective
interaction dTAFII16-PDS. It thus seems that the two
TAFIIs are functionally different in Drosophila.
In this context, specific mutant traits would be expected for these two
genes, although no mutations have thus far been identified in either of
them to confirm this point. We used PCR to analyze all available lethal
mutations in the area [l(2)AB2, l(2)AB3,
l(2)AB4, l(2)AB5, and l(2)AB6] (10,
39), and none showed sequence alterations in the ORF or the
genomic regions of either dTAFII. The chromosome Df(2)N6 is the only genetic variant available, and it
deletes both dTAFII genes. Since additional genes are
included, however, the lethality of this chromosome cannot be
attributed unequivocally to the dTAFII genes.
In addition to the sequence conservation and its functional association
with TBP for gene transcription, dTAFII16 localizes to the
nucleus at all developmental stages and tissues, as do all other
TAFIIs. In this context, we cannot confirm the
reported dual nuclear and cytoplasmic localization of
dTAFII16 (19). It may be relevant that
the antibodies used in the previous study were raised against peptide
sequences whereas those used here were obtained after immunization with
the whole protein. Data based on monospecific antibodies, crude serum,
and labeling of myc-tagged dTAFII16 localize the signal in
multiple spots within the nucleus only (Fig. 2). The hot spots at which
dTAFII16 appears to accumulate may correspond to
transcriptionally active regions.
Molecular mechanism and biological function of PDS.
Transfection experiments in Schneider 2 cells show that PDS activates
transcription when fused to the Gal4 DNA binding domain in a
dTAFII16- and TBP-dependent manner. The gene dosage effects on the expression of a Ras1 construct also support the role
of PDS as an activator rather than a repressor. In principle, this function could be achieved either as a bona fide transcription activator binding directly to DNA and recruiting TFIID to specific promoters or as a cofactor linking a true activator to the
transcription complex. Several arguments support PDS as a cofactor for
gene transcription. Cells transfected with PDS only fail to activate transcription of the luciferase reporter from the sev-Luc
construct. This experiment was designed to test whether PDS could use
enhancer or promoter sequences from the sevenless gene as
target, in view of the effects observed on the eye phenotype of
sev-Ras1V12 and the pds gene dosage.
It thus appears that to activate transcription, PDS requires
association with a DNA-binding activator. In the experiments with the
upstream activation sequence-Luc construct (Fig. 5), this effect was
provided by the DNA-binding domain of Gal4. This procedure of tethering
proteins to a promoter has served to infer a role of coactivators for
many components of several transcriptional complexes (20, 34,
62). The gene dosage modulation of the eye phenotype is probably
due to the titration effect on native components of the transcription machinery.
Through which transcription complex does PDS function? Extensive
biochemical work on preinitiation complex purification in several
organisms has failed to identify PDS so far, suggesting that PDS is not
a constitutive member of TFIID, and we have shown here that PDS does
not interact with TBP directly. These features prevent consideration of
PDS as a TAF, at least formally. Taken together, the available data
indicate that PDS is a novel transcriptional coactivator in which HFD
is the functional domain that mediates the interaction with
dTAFII16; this mechanism underlies a biological function
essential for cell survival. This observation, in addition to its
generalized expression in all tissues throughout development, as well
as its conserved sequence and requirement for cell survival, suggests
that many genes will be the target of PDS-mediated activation.
 |
ACKNOWLEDGMENTS |
We thank R. Tjian for plasmids (G4)5-HSV-TK-Luc and
pPac-
gal, D. A. Wassarman for plasmids pSP/HSS and pSE8/DM30,
S. Pons for anti-myc antibody (1-9E10.2), H. Bellen and the Bloomington and Umeå stock centers for mutant strains, and E. Hafen for
Raf and rough constructs. G. Marques provided key
training for experimental procedures. Laboratory members read the text critically.
This research was funded by grants 08.5/43/98 and PM96-006 from the
Comunidad Autónoma de Madrid (CAM) and the Spanish Ministry of
Culture (DGICYT), respectively. A. H.-H. is a CAM-funded
postdoctoral fellow.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Instituto Cajal,
C.S.I.C., Ave. Dr. Arce 37, 28002 Madrid, Spain. Phone: 34 915854739. Fax: 34 915854754. E-mail: aferrus{at}cajal.csic.es.
 |
REFERENCES |
| 1.
|
Apone, L. M.,
C. M. Virbasius,
J. C. Reese, and M. R. Green.
1996.
Yeast TAF(II)90 is required for cell-cycle progression through G2/M but not for general transcription activation.
Genes Dev.
10:2368-2380[Abstract/Free Full Text].
|
| 2.
|
Arents, G.,
R. W. Burlingame,
B. C. Wang,
W. E. Love, and E. N. Moudrianakis.
1991.
The nucleosomal core histone octamer at 3.1 A resolution: a tripartite protein assembly and a left-handed superhelix.
Proc. Natl. Acad. Sci. USA
88:10148-10152[Abstract/Free Full Text].
|
| 3.
|
Basler, K.,
P. Siegrist, and E. Hafen.
1989.
The spatial and temporal expression pattern of sevenless is exclusively controlled by gene-internal elements.
EMBO J.
8:2381-2386[Medline].
|
| 4.
|
Baxevanis, A. D.,
G. Arents,
E. N. Moudrianakis, and D. Landsman.
1995.
A variety of DNA-binding and multimeric proteins contain the histone fold motif.
Nucleic Acids Res.
23:2685-2691[Abstract/Free Full Text].
|
| 5.
|
Baxevanis, A. D., and D. Landsman.
1998.
Histone Sequence Database: new histone fold family members.
Nucleic Acids Res.
26:372-375[Abstract/Free Full Text].
|
| 6.
|
Birck, C.,
O. Poch,
C. Romier,
M. Ruff,
G. Mengus,
A. C. Lavigne,
I. Davidson, and D. Moras.
1998.
Human TAF(II)28 and TAF(II)18 interact through a histone fold encoded by atypical evolutionary conserved motifs also found in the SPT3 family.
Cell
94:239-249[CrossRef][Medline].
|
| 7.
|
Bowtell, D. D.,
T. Lila,
W. M. Michael,
D. Hackett, and G. M. Rubin.
1991.
Analysis of the enhancer element that controls expression of sevenless in the developing Drosophila eye.
Proc. Natl. Acad. Sci. USA
88:6853-6857[Abstract/Free Full Text].
|
| 8.
|
Chalkley, G. E., and C. P. Verrijzer.
1999.
DNA binding site selection by RNA polymerase II TAFs: a TAF(II)250-TAF(II)150 complex recognizes the initiator.
EMBO J.
18:4835-4845[CrossRef][Medline].
|
| 9.
|
Cherbas, L.,
R. Moss, and P. Cherbas.
1994.
Transformation techniques for Drosophila cell lines, p. 161-179.
In
L. S. B. Goldstein, and E. A. Fyrberg (ed.), Drosophila melanogaster:practical uses in cell and molecular biology. Academic Press, Inc., New York, N.Y.
|
| 10.
|
DiAntonio, A.,
K. D. Parfitt, and T. L. Schwarz.
1993.
Synaptic transmission persists in synaptotagmin mutants of Drosophila.
Cell
73:1281-1290[CrossRef][Medline].
|
| 11.
|
Dikstein, R.,
S. Ruppert, and R. Tjian.
1996.
TAFII250 is a bipartite protein kinase that phosphorylates the base transcription factor RAP74.
Cell
84:781-790[CrossRef][Medline].
|
| 12.
|
Feinberg, A. P., and B. Vogelstein.
1984.
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.
Anal. Biochem.
137:266-267[CrossRef][Medline].
|
| 13.
|
Felinski, E. A., and P. G. Quinn.
1999.
The CREB constitutive activation domain interacts with TATA-binding protein-associated factor 110 (TAF110) through specific hydrophobic residues in one of the three subdomains required for both activation and TAF110 binding.
J. Biol. Chem.
274:11672-11678[Abstract/Free Full Text].
|
| 14.
|
Ferreri, K.,
G. Gill, and M. Montminy.
1994.
The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex.
Proc. Natl. Acad. Sci. USA
91:1210-1213[Abstract/Free Full Text].
|
| 15.
|
Ferrús, A.
1975.
Parameters of mitotic recombination in minute mutants of Drosophila melanogaster.
Genetics
79:589-599[Abstract/Free Full Text].
|
| 16.
|
Fields, S., and O. Song.
1989.
A novel genetic system to detect protein-protein interactions.
Nature
340:245-246[CrossRef][Medline].
|
| 17.
|
Fortini, M. E.,
M. A. Simon, and G. M. Rubin.
1992.
Signalling by the sevenless protein tyrosine kinase is mimicked by Ras1 activation.
Nature
355:559-561[CrossRef][Medline].
|
| 18.
|
Gangloff, Y. G.,
S. Werten,
C. Romier,
L. Carre,
O. Poch,
D. Moras, and I. Davidson.
2000.
The human TFIID components TAF(II)135 and TAF(II)20 and the yeast SAGA components ADA1 and TAF(II)68 heterodimerize to form histone-like pairs.
Mol. Cell. Biol.
20:340-351[Abstract/Free Full Text].
|
| 19.
|
Georgieva, S.,
D. B. Kirschner,
T. Jagla,
E. Nabirochkina,
S. Hanke,
H. Schenkel,
C. de Lorenzo,
P. Sinha,
K. Jagla,
B. Mechler, and L. Tora.
2000.
Two novel Drosophila TAF(II)s have homology with human TAF(II)30 and are differentially regulated during development.
Mol. Cell. Biol.
20:1639-1648[Abstract/Free Full Text].
|
| 20.
|
Gonzalez-Couto, E.,
N. Klages, and M. Strubin.
1997.
Synergistic and promoter-selective activation of transcription by recruitment of transcription factors TFIID and TFIIB.
Proc. Natl. Acad. Sci. USA
94:8036-8041[Abstract/Free Full Text].
|
| 21.
|
Goodrich, J. A.,
T. Hoey,
C. J. Thut,
A. Admon, and R. Tjian.
1993.
Drosophila TAFII40 interacts with both a VP16 activation domain and the basal transcription factor TFIIB.
Cell
75:519-530[CrossRef][Medline].
|
| 22.
|
Grant, P. A.,
D. Schieltz,
M. G. Pray-Grant,
D. J. Steger,
J. C. Reese,
J. R. Yates, and J. L. Workman.
1998.
A subset of TAF(II)s are integral components of the SAGA complex required for nucleosome acetylation and transcriptional stimulation.
Cell
94:45-53[CrossRef][Medline].
|
| 23.
|
Hahn, S.
1998.
The role of TAFs in RNA polymerase II transcription.
Cell
95:579-582[CrossRef][Medline].
|
| 24.
|
Hampsey, M.
1998.
Molecular genetics of the RNA polymerase II general transcriptional machinery.
Microbiol. Mol. Biol. Rev.
62:465-503[Abstract/Free Full Text].
|
| 25.
|
Hansen, S. K.,
S. Takada,
R. H. Jacobson,
J. T. Lis, and R. Tjian.
1997.
Transcription properties of a cell type-specific TATA-binding protein, TRF.
Cell
91:71-83[CrossRef][Medline].
|
| 26.
|
Harlow, E., and D. Lane.
1988.
Antibodies: a laboratory manual.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 27.
|
Harper, J. W.,
G. R. Adami,
N. Wei,
K. Keyomarsi, and S. J. Elledge.
1993.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Cell
75:805-816[CrossRef][Medline].
|
| 28.
|
Hengen, P. N.
1997.
False positives from the yeast two-hybrid system.
Trends Biochem. Sci.
22:33-34[CrossRef][Medline].
|
| 29.
|
Hoey, T.,
R. O. Weinzierl,
G. Gill,
J. L. Chen,
B. D. Dynlacht, and R. Tjian.
1993.
Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators.
Cell
72:247-260[CrossRef][Medline].
|
| 30.
|
Hoffmann, A.,
C. M. Chiang,
T. Oelgeschlager,
X. Xie,
S. K. Burley,
Y. Nakatani, and R. G. Roeder.
1996.
A histone octamer-like structure within TFID.
Nature
380:356-359[CrossRef][Medline].
|
| 31.
|
Hoffmann, A.,
T. Oelgeschlager, and R. G. Roeder.
1997.
Considerations of transcriptional control mechanisms: do TFIID-core promoter complexes recapitulate nucleosome-like functions?
Proc. Natl. Acad. Sci. USA
94:8928-8935[Abstract/Free Full Text].
|
| 32.
|
Jacq, X.,
C. Brou,
Y. Lutz,
I. Davidson,
P. Chambon, and L. Tora.
1994.
Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor.
Cell
79:107-117[CrossRef][Medline].
|
| 33.
|
Karim, F. D.,
H. C. Chang,
M. Therrien,
D. A. Wassarman,
T. Laverty, and G. M. Rubin.
1996.
A screen for genes that function downstream of Ras1 during Drosophila eye development.
Genetics
143:315-329[Abstract].
|
| 34.
|
Keaveney, M., and K. Struhl.
1998.
Activator-mediated recruitment of the RNA polymerase II machinery is the predominant mechanism for transcriptional activation in yeast.
Mol. Cell
1:917-924[CrossRef][Medline].
|
| 35.
|
Klemm, R. D.,
J. A. Goodrich,
S. Zhou, and R. Tjian.
1995.
Molecular cloning and expression of the 32-kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation.
Proc. Natl. Acad. Sci. USA
92:5788-5792[Abstract/Free Full Text].
|
| 36.
|
Koleske, A. J., and R. A. Young.
1995.
The RNA polymerase II holoenzyme and its implications for gene regulation.
Trends Biochem. Sci.
20:113-116[CrossRef][Medline].
|
| 37.
|
Lavigne, A. C.,
G. Mengus,
Y. G. Gangloff,
J. M. Wurtz, and I. Davidson.
1999.
Human TAF(II)55 interacts with the vitamin D(3) and thyroid hormone receptors and with derivatives of the retinoid X receptor that have altered transactivation properties.
Mol. Cell. Biol.
19:5486-5494[Abstract/Free Full Text].
|
| 38.
|
Lee, T. I., and R. A. Young.
1998.
Regulation of gene expression by TBP-associated proteins.
Genes Dev.
12:1398-1408[Free Full Text].
|
| 39.
|
Littleton, J. T., and H. J. Bellen.
1994.
Genetic and phenotypic analysis of thirteen essential genes in cytological interval 22F1-2; 23B1-2 reveals novel genes required for neural development in Drosophila.
Genetics
138:111-123[Abstract].
|
| 40.
|
Lu, H., and A. J. Levine.
1995.
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
Proc. Natl. Acad. Sci. USA
92:5154-5158[Abstract/Free Full Text].
|
| 41.
|
Maity, S. N., and B. de Crombrugghe.
1998.
Role of the CCAAT-binding protein CBF/NF-Y in transcription.
Trends Biochem. Sci.
23:174-178[CrossRef][Medline].
|
| 42.
|
Martin, J.,
R. Halenbeck, and J. Kaufmann.
1999.
Human transcription factor hTAF(II)150 (CIF150) is involved in transcriptional regulation of cell cycle progression.
Mol. Cell. Biol.
19:5548-5556[Abstract/Free Full Text].
|
| 43.
|
Martinez, E.,
T. K. Kundu,
J. Fu, and R. G. Roeder.
1998.
A human SPT3-TAFII31-GCN5-L acetylase complex distinct from transcription factor IID.
J. Biol. Chem.
273:23781-23785[Abstract/Free Full Text].
|
| 44.
|
May, M.,
G. Mengus,
A. C. Lavigne,
P. Chambon, and I. Davidson.
1996.
Human TAF(II28) promotes transcriptional stimulation by activation function 2 of the retinoid X receptors.
EMBO J.
15:3093-3104[Medline].
|
| 45.
|
Metzger, D.,
E. Scheer,
A. Soldatov, and L. Tora.
1999.
Mammalian TAF(II)30 is required for cell cycle progression and specific cellular differentiation programmes.
EMBO J.
18:4823-4834[CrossRef][Medline].
|
| 46.
|
Mizzen, C. A.,
X. J. Yang,
T. Kokubo,
J. E. Brownell,
A. J. Bannister,
T. Owen-Hughes,
J. Workman,
L. Wang,
S. L. Berger,
T. Kouzarides,
Y. Nakatani, and C. D. Allis.
1996.
The TAF(II)250 subunit of TFIID has histone acetyltransferase activity.
Cell
87:1261-1270[CrossRef][Medline].
|
| 47.
|
Moqtaderi, Z.,
Y. Bai,
D. Poon,
P. A. Weil, and K. Struhl.
1996.
TBP-associated factors are not generally required for transcriptional activation in yeast.
Nature
383:188-191[CrossRef][Medline].
|
| 48.
|
Mount, S. M.,
C. Burks,
G. Hertz,
G. D. Stormo,
O. White, and C. Fields.
1992.
Splicing signals in Drosophila: intron size, information content, and consensus sequences.
Nucleic Acids Res.
20:4255-4262[Abstract/Free Full Text].
|
| 49.
|
O'Brien, T., and R. Tjian.
1998.
Functional analysis of the human TAFII250 N-terminal kinase domain.
Mol. Cell
1:905-911[CrossRef][Medline].
|
| 50.
|
Oelgeschlager, T.,
Y. Tao,
Y. K. Kang, and R. G. Roeder.
1998.
Transcription activation via enhanced preinitiation complex assembly in a human cell-free system lacking TAFIIs.
Mol. Cell
1:925-931[CrossRef][Medline].
|
| 51.
|
Ogryzko, V. V.,
T. Kotani,
X. Zhang,
R. L. Schlitz,
T. Howard,
X. J. Yang,
B. H. Howard,
J. Qin, and Y. Nakatani.
1998.
Histone-like TAFs within the PCAF histone acetylase complex.
Cell
94:35-44[CrossRef][Medline].
|
| 52.
|
Orphanides, G.,
T. Lagrange, and D. Reinberg.
1996.
The general transcription factors of RNA polymerase II.
Genes Dev.
10:2657-2683[Free Full Text].
|
| 53.
|
Ortiz, L.,
P. Aza-Blanc,
M. Zannini,
A. C. Cato, and P. Santisteban.
1999.
The interaction between the forkhead thyroid transcription factor TTF-2 and the constitutive factor CTF/NF-1 is required for efficient hormonal regulation of the thyroperoxidase gene transcription.
J. Biol. Chem.
274:15213-15221[Abstract/Free Full Text].
|
| 54.
|
Pham, A. D.,
S. Muller, and F. Sauer.
1999.
Mesoderm-determining transcription in Drosophila is alleviated by mutations in TAF(II)60 and TAF(II)110.
Mech. Dev.
84:3-16[CrossRef][Medline].
|
| 55.
|
Prado, A.,
I. Canal, and A. Ferrus.
1999.
The haplolethal region at the 16F gene cluster of Drosophila melanogaster: structure and function.
Genetics
151:163-175[Abstract/Free Full Text].
|
| 56.
|
Roeder, R. G.
1996.
The role of general initiation factors in transcription by RNA polymerase II.
Trends Biochem. Sci.
21:327-335[CrossRef][Medline].
|
| 57.
|
Rojo-Niersbach, E.,
T. Furukawa, and N. Tanese.
1999.
Genetic dissection of hTAF(II)130 defines a hydrophobic surface required for interaction with glutamine-rich activators.
J. Biol. Chem.
274:33778-33784[Abstract/Free Full Text].
|
| 58.
|
Saluja, D.,
M. F. Vassallo, and N. Tanese.
1998.
Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators.
Mol. Cell. Biol.
18:5734-5743[Abstract/Free Full Text].
|
| 59.
|
Sauer, F.,
S. K. Hansen, and R. Tjian.
1995.
Multiple TAFIIs directing synergistic activation of transcription.
Science
270:1783-1788[Abstract/Free Full Text].
|
| 60.
|
Sauer, F.,
D. A. Wassarman,
G. M. Rubin, and R. Tjian.
1996.
TAF(II)s mediate activation of transcription in the Drosophila embryo.
Cell
87:1271-1284[CrossRef][Medline].
|
| 61.
|
Shen, W. C., and M. R. Green.
1997.
Yeast TAF(II)145 functions as a core promoter selectivity factor, not a general coactivator.
Cell
90:615-624[CrossRef][Medline].
|
| 62.
|
Stargell, L. A.,
Z. Moqtaderi,
D. R. Dorris,
R. C. Ogg, and K. Struhl.
2000.
TFIIA has activator-dependent and core promoter functions in vivo.
J. Biol. Chem.
275:12374-12380[Abstract/Free Full Text].
|
| 63.
|
Struhl, K., and Z. Moqtaderi.
1998.
The TAFs in the HAT.
Cell
94:1-4[CrossRef][Medline].
|
| 64.
|
Swevers, L.,
L. Cherbas,
P. Cherbas, and K. Iatrou.
1996.
Bombyx EcR (BmEcR) and Bombyx USP (BmCF1) combine to form a functional ecdysone receptor.
Insect Biochem. Mol. Biol.
26:217-221[CrossRef][Medline].
|
| 65.
|
Tanese, N.,
D. Saluja,
M. F. Vassallo,
J. L. Chen, and A. Admon.
1996.
Molecular cloning and analysis of two subunits of the human TFIID complex: hTAFII130 and hTAFII100.
Proc. Natl. Acad. Sci. USA
93:13611-13616[Abstract/Free Full Text].
|
| 66.
|
Tansey, W. P., and W. Herr.
1997.
TAFs: guilt by association?
Cell
88:729-732[CrossRef][Medline].
|
| 67.
|
Thut, C. J.,
J. L. Chen,
R. Klemm, and R. Tjian.
1995.
p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.
Science
267:100-104[Abstract/Free Full Text].
|
| 68.
|
Torroja, L.,
D. Ortuno-Sahagun,
A. Ferrus,
B. Hammerle, and J. A. Barbas.
1998.
scully, an essential gene of Drosophila, is homologous to mammalian mitochondrial type II L-3-hydroxyacyl-CoA dehydrogenase/amyloid-beta peptide-binding protein.
J. Cell Biol.
141:1009-1017[Abstract/Free Full Text].
|
| 69.
|
Verrijzer, C. P.,
J. L. Chen,
K. Yokomori, and R. Tjian.
1995.
Binding of TAFs to core elements directs promoter selectivity by RNA polymerase II.
Cell
81:1115-1125[CrossRef][Medline].
|
| 70.
|
|